



(51) International Patent Classification:

C07D 231/40 (2006.01) **C07D 413/14** (2006.01)
C07D 401/12 (2006.01) **C07D 417/12** (2006.01)
C07D 401/14 (2006.01) **C07D 417/14** (2006.01)
C07D 403/12 (2006.01) **C07D 471/04** (2006.01)
C07D 403/14 (2006.01) **C07D 487/04** (2006.01)
C07D 405/12 (2006.01) **C07D 513/04** (2006.01)
C07D 405/14 (2006.01) **A61K 31/415** (2006.01)
C07D 413/12 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/IB2020/050653

(22) International Filing Date:

28 January 2020 (28.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/799,455 31 January 2019 (31.01.2019) US
 62/959,042 09 January 2020 (09.01.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors: **BEHENNA, Douglas Carl**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **FREEMAN-COOK, Kevin Daniel**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **HOFFMAN, Robert Louis**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **NAGATA, Asako**; c/o

o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **NINKOVIC, Sacha**; c/o Pfizer Inc., 10777 Science Center, San Diego, CA 92121 (US). **SUTTON, Scott Channing**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: 3-CARBONYLAMINO-5-CYCLOPENTYL-1 FI-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2





FIG. 1



(57) Abstract: This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R^1 , R^2 and R^3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

10 September 2020 (10.09.2020)